Fibrocystic Breast Condition Market Report 2025

The fibrocystic breast condition market size has grown strongly in recent years. It will grow from $6.74 billion in 2024 to $7.17 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historical period can be attributed to the increasing prevalence of breast cancer, higher healthcare expenditure, urbanization, greater awareness, lifestyle changes, and elevated disposable income.

The fibrocystic breast condition market size is expected to see strong growth in the next few years. It will grow to $9.1 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to the increasing demand for diagnostic tools and treatments, rising government funding, growing need for effective therapies, an expanding geriatric population, initiatives by public and private organizations, and heightened research and development activities. Key trends expected in this period include the adoption of minimally invasive breast biopsy devices, strategic partnerships and collaborations, a greater emphasis on personalized medicine, the integration of artificial intelligence (AI), and continuous technological advancements.

The increasing prevalence of breast cancer is expected to drive the growth of the fibrocystic breast condition market. Breast cancer is a type of cancer that originates in the cells of the breast and primarily affects women. Factors such as an aging population, unhealthy lifestyles, genetic predisposition, increased screening, and environmental exposures contribute to its rising occurrence. Fibrocystic breast condition (FBC) may elevate the risk of breast cancer by leading to dense breast tissue, which can promote cellular changes, heightened hormone sensitivity, and prolonged inflammation, creating an environment that may facilitate cancer development. For example, in July 2024, the American Cancer Society Facts and Figures reported that the number of new breast cancer cases in the United States is expected to rise from 300,590 in 2023 to 313,510 in 2024. As a result, the growing prevalence of breast cancer is fueling the expansion of the fibrocystic breast condition market.

The increasing availability of telemedicine services is contributing to the growth of the fibrocystic breast condition market. Telemedicine services utilize digital communication technologies, such as video calls, mobile applications, and online platforms, to provide remote medical consultations, diagnosis, and treatment. The expansion of telemedicine is driven by the growing adoption of digital health platforms, improved internet accessibility, and patient preferences for remote healthcare services. For individuals with fibrocystic breast condition, telemedicine enables remote consultations, timely symptom management, and expert medical guidance, reducing the necessity for in-person visits and enhancing patient convenience. For instance, in February 2023, Rock Health, a US-based corporation, reported that 80% of respondents in its 2022 survey had used telemedicine services at some point, reflecting an 8 percentage point increase from 72% in 2021. This increased access to telemedicine is contributing to the expansion of the fibrocystic breast condition market.

Leading companies in the fibrocystic breast condition market are developing advanced diagnostic technologies to enhance diagnostic accuracy and treatment outcomes. Diagnostic devices are tools used to detect, identify, or assess medical conditions and diseases. In August 2024, Izotropic Corporation, a Canada-based medical device company, introduced IzoView, a breast CT imaging system designed to improve breast cancer diagnosis in women with dense breast tissue. The company is seeking regulatory approval through a clinical study aimed at demonstrating the superior diagnostic performance of IzoView when used alongside digital breast tomosynthesis (DBT) compared to DBT alone. With high-resolution 3D imaging capabilities and the advantage of eliminating the need for breast compression, IzoView aims to enhance breast cancer detection rates in women with dense breast tissue, a group at higher risk for developing the disease.

Major players in the fibrocystic breast condition market are Pfizer Inc., Hitachi Medical Systems, Roche Diagnostics, Merck & Co Inc., Bayer AG, Sanofi SA, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Fujifilm Holdings Corporation, Philips Healthcare, Becton Dickinson and Company, GE Healthcare Technologies Inc., Teva Pharmaceutical Industries Ltd, Hologic Inc., Canon Medical Systems Corporation, Hikma Pharmaceuticals plc, Steris Pharma, Lannett Company Inc., Argon Medical Devices Inc., and AdvaCare Pharma USA LLC.

North America was the largest region in the fibrocystic breast condition market in 2024. The regions covered in fibrocystic breast condition report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the fibrocystic breast condition market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Fibrocystic breast condition (FBC) is a noncancerous disorder marked by lumpiness, tenderness, and pain in one or both breasts due to the presence of fibrous tissue and fluid-filled cysts. This common benign breast condition is primarily linked to hormonal fluctuations and mostly affects women of reproductive age. Symptoms often change throughout the menstrual cycle and usually subside after menopause.

Treatment options for fibrocystic breast condition include medications, oral contraceptives, fine-needle aspiration, and other approaches. Medications, such as over-the-counter pain relievers or hormonal therapies in severe cases, help alleviate pain and tenderness. Diagnosis involves various methods, including mammograms, ultrasounds, clinical breast exams, and other diagnostic techniques. The condition is managed in different healthcare settings, including hospitals, clinics, and other medical facilities.

The fibrocystic breast condition market research report is one of a series of new reports that provides fibrocystic breast condition market statistics, including the fibrocystic breast condition industry global market size, regional shares, competitors with the fibrocystic breast condition market share, detailed fibrocystic breast condition market segments, market trends, and opportunities, and any further data you may need to thrive in the fibrocystic breast condition industry. This fibrocystic breast condition market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fibrocystic breast condition market consists of revenues earned by entities by providing services such as diagnosis and screening services, surgical interventions, healthcare consultations and follow-ups, medical treatments, and medications. The market value includes the value of related goods sold by the service provider or included within the service offering. The fibrocystic breast condition market also includes sales of hormonal therapies, ultrasound devices, cyst aspiration kits, vitamins, and supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.